3
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Thoracic
1
Conditions
EGFR T790M Mutation Positive NSCLC
1
Interventions
trametinib
4
nilotinib
4
elotuzumab
4
dabrafenib
4
Amifampridine
4
regorafenib
3
pembrolizumab
3
midostaurin
3
fludarabine phosphate
3
fludarabine
3
Nivolumab
3
Lenalidomide
3
Ipilimumab
3
Everolimus
3
Dexamethasone
3
Cyclophosphamide
3
Crizotinib
3
Bortezomib
3
Axitinib
3
venetoclax
2
veliparib
2
tazemetostat
2
talimogene laherparepvec
2
navitoclax
2
gallium 68 PSMA-11
2
ceritinib
2
carbon-11 acetate
2
aldesleukin
2
Whole-Body Irradiation
2
Trabectedin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
No longer available
×
Expanded_access
×
osimertinib
×
Clear all
NCT02451852
2016-07-14
AZD9291 US Expanded Access Program
AstraZeneca
No longer available